Suppressing GRP78 Halts Prostate Cancer Development

Hot Topics - Tumor growth

Suppressing GRP78 Halts Prostate Cancer Development

PrintE-mail

Inactivating a specific biomarker for aggressive prostate cancer, called GRP78, blocks the development of prostate cancer in animal models according to researchers at the University of Southern California (USC). This breakthrough discovery may lead to a novel cancer therapy for humans.

"This research has far-reaching implications in a wide range for human cancers," says Amy Lee, Ph.D., the study’s principal investigator.  Lee helps direct basic research at USC/Norris Comprehensive Cancer Center and teaches biochemistry and molecular biology at the Keck School of Medicine of USC.

 Prostate cancer is the most common cancer in men and develops through successive stages. The glucose-regulated protein GRP78 has been identified as a crucial entity in the development of prostate cancer by in creases in cancer cells (proliferation), passing chemical messages between cancer cells (mediating oncogenic signaling) and protecting cancer cells against cell death resulting from the stress of tumor development, Lee explains.

By suppressing GRP78 expression or activity, the USC researchers found that they could block prostate cancer activation and development resulting from the loss of PTEN, a powerful tumor suppressor gene for a number of human cancers.

Researchers spent more than three years monitoring prostate cancer development in animal models that had been genetically engineered to have both the GRP78 and PTEN tumor suppressor genes inactivated.

Future research should test the role of GRP78 in other types of cancer and isolate drugs that inhibit GRP78, Lee says.

"To our knowledge, this is the first demonstration that inactivation of a specific molecular chaperone from the mouse prostate epithelial cells can potently block prostate cancer development and suppress the activation of AKT, which is a protein kinase that promotes cell proliferation and survival and is a major factor in many types of cancer," Lee says. "With the recent advances in identifying agents that suppress GRP78 expression, anti-GRP78 therapy may open up an entirely new approach to stop human cancer."

Edited by J. Strax.

The study was funded by a grant from the National Cancer Institute that has been awarded to Amy Lee for the past 28 years. She holds the Freeman Cosmetics Chair at the USC/Norris Comprehensive Cancer Center and a professorship at the Keck School.

The study is scheduled for publication in Proceedings of the National Academy of Sciences, now available online:

Yong Fu, Shiuan Wey, Miao Wang, Risheng Ye, Chun-Peng Liao, Pradip Roy-Burman, and Amy S. Lee.  Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium.  Proceedings of National Academy of Sciences. Nov. 2008. 

Hot Topics - Tumor growth